药品定价政策技术咨询小组：会议报告，2025年11月19日

Technical Advisory Group on Pricing Policies for Medicines:meeting report, 19 November 2025 © World Health Organization 2026 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike3.0IGO licence (CCBY-NC-SA3.0IGO;https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes,provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestionthat WHO endorses any specificorganization, products or services. The use of the WHO logo is not permitted. If youadapt the work, then you must license your work under the same or equivalent Creative Commons licence. If youcreate a translation of this work, you should add the following disclaimer along with the suggested citation:“This Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediationrules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation. Technical Advisory Group on Pricing Policies for Medicines: meeting report, 19 November2025. Geneva: World Health Organization;2026.https://doi.org/10.2471/B09716. Licence:CCBY-NC-SA3.0IGO. Cataloguing-in-Publication (CIP) data.CIP data are available athttps://iris.who.int/. Sales, rights and licensing.To purchase WHO publications, seehttps://www.who.int/publications/book-orders. Tosubmit requests for commercial use and queries on rights and licensing, seehttps://www.who.int/copyright. Third-party materials.If you wish to reuse material from this work that is attributed to a third party, such as tables,figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain General disclaimers.The designations employed and the presentation of the material in this publication do notimply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country,territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed orrecommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions All reasonable precautions have been taken by WHO to verify the information contained in this publication.However, the published material is being distributed without warranty of any kind, either expressed or implied. Theresponsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for This publication contains the report of the Technical Advisory Group on Pricing Policies for Medicines and does not Contents Executive summary...................................................................................................................................................................iv 1.1Establishment of TAG-PPM................................................................................................................................................11.2Meeting objectives and process.......................................................................................................................................1 2.Workstreams and discussion summary....................................................................................................................2 2.1Workstream I: Proposing a set of economic evidence to guide decision making for medicine listing in aglobal context.........................................................................................................................................................................22.2Workstream II: Assessing the real-world economic, social, and political implications of non-transparentprices and initiatives to increase price transparency in health and other sectors..............................................5 References...................................................................................................................................................................................7 Annex 1. TAG-PPM and meeting participants....................................................................................................................8 Annex 2. Meeting agenda.......................................................................................................................................................9 Executive summary On19 November2025, the World Health Organization (WHO) convened the Technical Advisory Group onPricingPolicies for Medicines(TAG-PPM). The purpose of the meeting was to review its work programme, assess progress, TheTAG-PPMconsolidated its work programme into two thematic areas: (i) proposing a set of economic evidenceto guidedecision makingfor medicine listing